Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Manufacturing
WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems
By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Pharmaceutical
Azelis strengthens its footprint in Italy with the acquisition of Azienda Chimica e Farmaceutica (‘ACEF’)
Azelis is pleased to announce that it has acquired 100% of the shares of Azienda Chimica e Farmaceutica (‘ACEF’), a distributor of speciality raw materials and ingredients for the cosmetic, nutraceutical, galenic and pharma industries in Italy
Manufacturing
Atlas Copco expands oil-free compressor range to support critical pharmaceutical air quality standards
Atlas Copco has expanded its oil-free compressor portfolio with cutting-edge models engineered to exceed pharmaceutical air quality standards and improve energy efficiency across critical manufacturing environments